Pacific Edge Limited announced the appointment of Dr. Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer. Dr. Meintjes, brings to Pacific Edge extensive global diagnostics, biotechnology, and commercial leadership expertise. He also has a track record for commercializing new and disruptive biotechnologies and driving rapid business growth across multiple territories including the U.S. and Europe. He will take up the role on 10 January 2022 replacing Executive Director and Chief Executive David Darling, who announced his retirement in April 2021 and will step down from the CEO role and the Board of Directors on the January 10 and continue as a consultant to the company. Dr. Meintjes' most recent role was Chief Commercial Officer at the Eurofins-Transplant Genomics. In that role he led the commercialisation of the company's suite of tests for biomarkers of organ rejection, including the product TruGraf.